Adage Capital Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Adage Capital Partners’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63.1M	Buy	725,744 +104,159	+17%	+$10.1M	0.1%	213
2025 Q4	$66.5M	Buy	621,585 +77,585	+14%	+$8.23M	0.1%	196
2025 Q3	$54.9M	Buy	544,000 +203,000	+60%	+$18.8M	0.09%	220
2025 Q2	$21.5M	Buy	+341,000	New	+$20.9M	0.04%	435
2023 Q4	–	Sell	-43,815	Closed	-$1M	–	921
2023 Q3	$1M	Buy	+43,815	New	+$981K	﹤0.01%	765
2020 Q2	–	Sell	-25,000	Closed	-$381K	–	794
2020 Q1	$381K	Hold	25,000	–	–	﹤0.01%	707
2019 Q4	$574K	Hold	25,000	–	–	﹤0.01%	693
2019 Q3	$540K	Hold	25,000	–	–	﹤0.01%	702
2019 Q2	$550K	Hold	25,000	–	–	﹤0.01%	693
2019 Q1	$685K	Buy	+25,000	New	+$718K	﹤0.01%	669
2018 Q4	–	Sell	-25,000	Closed	-$729K	–	746
2018 Q3	$729K	Buy	+25,000	New	+$790K	﹤0.01%	698

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Adage Capital Partners's RYTM Position: Q1 2026 in Review

Adage Capital Partners increased its Rhythm Pharmaceuticals (RYTM) stake by 17% in Q1 2026, buying an estimated $10.1M and bringing the position to 725,744 shares worth $63.1M. The position accounts for 0.1% of the portfolio, ranked #213.

Adage Capital Partners first reported a position in RYTM in Q3 2018 and has held it in 11 quarters since. The position peaked at $66.5M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Adage Capital Partners held 725,744 shares of Rhythm Pharmaceuticals worth $63.1M as of Q1 2026.
Adage Capital Partners bought 104,159 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $10.1M.
Rhythm Pharmaceuticals made up 0.1% of Adage Capital Partners's portfolio in Q1 2026, its #213 holding.
Adage Capital Partners first reported a position in Rhythm Pharmaceuticals in Q3 2018 and has held it in 11 quarters since.
Adage Capital Partners's Rhythm Pharmaceuticals position peaked at $66.5M in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.